Bristol Myers Squibb said Zenbexus, which received FDA accelerated approval to treat multiple myeloma, reduced the risk of disease progression by 51% versus standard therapy in a Phase 3 trial. The update highlights the continued role of accelerated pathways in moving new regimens into the clinic while confirming efficacy in late-stage data. For biotech operators, the company’s disclosure reinforces the regulatory and competitive value of demonstrating durable progression outcomes in confirmatory settings. The Phase 3 reduction provides a clear performance anchor for payors and subsequent line-of-therapy positioning. Market participants will likely scrutinize how Zenbexus integrates into existing multi-agent standards and whether additional endpoints (such as overall survival and response durability) are expected in upcoming presentations or filings.